Jagsonpal Pharmaceuticals (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Jagsonpal Pharmaceuticals Limited |
|||
|
Price: ₹254.90 (+11.68%) | ||
| 52 Week Low: ₹196.35 52 Week High: ₹820.10 |
|||
| Market Capital: 1,489.2 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Jagsonpal Pharmaceuticals Share Price Target For 2025
- 1.1.1: Jagsonpal Pharmaceuticals Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Jagsonpal Pharmaceuticals Share Price Target For 2026
- 1.2.1: Jagsonpal Pharmaceuticals Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Jagsonpal Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Jagsonpal Pharmaceuticals Brief Company Overview
- 4: Jagsonpal Pharmaceuticals Financial Performance
- 4.0.1: Is Jagsonpal Pharmaceuticals A Good Buy For Long Term?
Jagsonpal Pharmaceuticals, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 815.3% returns in 5-year showing 29.2% quarterly revenue growth with 10.7% profit margin, making it a potential Multibagger.
To predict the Jagsonpal Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Jagsonpal Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Jagsonpal Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Jagsonpal Pharmaceuticals shares in 2025, see the table below.
Jagsonpal Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 359.3 (+40.95%) | Price Action: 06 May 2024 High |
| 2025 Target 2 | 352.65 (+38.34%) | Price Action: 19 Aug 2024 Low |
| 2025 Target 1 | 348.6 (+36.75%) | Price Action: 22 Jul 2024 High |
| Current Price | 254.90 | Jagsonpal Pharmaceuticals's share price as of 23 Jan 2025 |
| Stop Loss 1 | 212.0 (-16.84%) | Price Action: 16 Jan 2025 Low |
| Stop Loss 2 | 209.88 (-17.67%) | Price Action: Chart |
| Stop Loss 3 | 206.0 (-19.19%) | Price Action: 15 Jan 2025 Low |
Short-Term Technical Outlook
Current Technical Position: Jagsonpal Pharmaceuticals is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹441.16 serves as the nearest technical reference point.
Historical Returns: 3-month: -53.03% | 6-month: -31.18% | 1-year: -30.87%
Jagsonpal Pharmaceuticals Share Price Target For 2026
The line chart displays the monthly closing prices of Jagsonpal Pharmaceuticals with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Jagsonpal Pharmaceuticals shares in 2026, see the table below.
Jagsonpal Pharmaceuticals Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 647.45 (+154%) | Price Action: 13 Dec 2024 Low |
| 2026 Target 2 | 637.9 (+150.25%) | Price Action: 26 Dec 2024 High |
| 2026 Target 1 | 630.6 (+147.38%) | Price Action: 24 Dec 2024 Low |
| Current Price | 254.90 | Jagsonpal Pharmaceuticals's share price as of 23 Jan 2025 |
| Stop Loss 1 | 156.32 (-38.68%) | Price Action: Chart |
| Stop Loss 2 | 154.76 (-39.29%) | Price Action: Chart |
| Stop Loss 3 | 151.97 (-40.39%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Jagsonpal Pharmaceuticals is currently trading near its 52-week low of ₹196.35, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -30.87% | 3-year: +56.48% | 5-year: +815.26%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Jagsonpal Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹254.90 | ||
| 2025 | ₹1,132.63 | +344.34% | ₹1,149.62 |
| 2026 | ₹1,627.12 | +43.65% | ₹1,651.53 |
| 2027 | ₹2,458.24 | +51.07% | ₹2,495.11 |
| 2028 | ₹3,362.51 | +36.78% | ₹3,412.95 |
| 2029 | ₹4,816.52 | +43.24% | ₹4,888.77 |
| 2030 | ₹6,590.46 | +36.83% | ₹6,689.32 |
| 2031 | ₹9,641.77 | +46.29% | ₹9,786.40 |
| 2032 | ₹11,716.25 | +21.51% | ₹11,891.99 |
| 2033 | ₹14,207.74 | +21.26% | ₹14,420.86 |
| 2034 | ₹19,484.45 | +37.13% | ₹19,776.72 |
| 2035 | ₹26,309.77 | +35.02% | ₹26,704.42 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Jagsonpal Pharmaceuticals Brief Company Overview
Company Overview: Jagsonpal Pharmaceuticals Limited Established in 1978, Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company headquartered in New Delhi, India. The company specializes in manufacturing and trading pharmaceutical products and active...
pharmaceutical ingredients in various therapeutic areas. Key Products and Services: Pharmaceutical formulations and over-the-counter drugs Women's health Pain and analgesics General medicine Jagsonpal Pharmaceuticals offers a diverse range of products, including tablets, softgels, injections, capsules, and syrups. Their products cater to the needs of individuals and healthcare providers in India and international markets. Reputation and Commitment: Jagsonpal Pharmaceuticals has earned a strong reputation in the industry for its commitment to quality and innovation. The company adheres to stringent manufacturing standards and is dedicated to providing affordable and accessible healthcare solutions to patients.Jagsonpal Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,489.2 Crore | Market valuation of Jagsonpal Pharmaceuticals's shares. |
| Revenue (TTM) | 226.85 Crore | Total revenue generated by Jagsonpal Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +24.3 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +18.66% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +10.71% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+29.2% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+53.4% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
4.97 | Company's total debt divided by total shareholder equity. |
| Total Debt | 9.81 Crore | Sum of Jagsonpal Pharmaceuticals's current & long-term financial obligations. |
| Total Cash | 77.84 Crore | Total amount of liquid funds available to Jagsonpal Pharmaceuticals. |
| Beta | 1.05 | Beta is greater than 1 indicating that the Jagsonpal Pharmaceuticals's price is more volatile than the market. |
Is Jagsonpal Pharmaceuticals A Good Buy For Long Term?
Jagsonpal Pharmaceuticals, a small-cap stock with a market cap of ₹1,489.2 crore, shows strong recent performance: 70.64% return in the last 3 months and a staggering 1927.41% return over 5 years. While Q2 2024-25 saw a healthy cash balance of ₹77.84 crore and a net profit of ₹24.3 crore (10.71% profit margin), its relatively small size and debt of ₹9.81 crore present some risk. Considering the exceptional past returns and growth, it could be a good buy for long-term investors with a high-risk tolerance, but thorough due diligence is crucial.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
